The report challenges the assertions made by pro-transgender medical groups, activists, and those in the Biden administration that puberty blockers and cross-sex hormones decrease suicides among minors who think they're sexually different.
The 25 page report, created by Senior Research Fellow, Dr. Jay Greene, analyzes current research on the efficacy of these therapies in preventing suicide among youth. Greene discovered, in line with the recent report released from Florida Medicaid, that current research “fail[s] to show a causal relationship and [has] been poorly executed.”
The writer took his study one step further by conducting research using what he described as a “superior research design.” He concluded “that easing access to puberty blockers and cross-sex hormones by minors without parental consent increases suicide rates.”
The Key Findings:
“Superior Research Design”
Greene’s study states that there are laws that permit minors access to routine medical services without parental permission — rules which “were developed for reasons that have nothing to do with gender identity.”
Greene's study “exploits this natural policy experiment” to analyze the rates of suicide for people between the ages of 12 to 23 in states which require parental consent for medical treatment and states that don't.
He specifically examined suicides that took place between 1999 and 2020 in this age range because individuals could have hit puberty between the years 2010 and 2020 in the time frame when puberty blockers and cross-sex hormones were introduced as a “gender-related treatment” in the United States, according to the report. Greene posed:
Making it possible for minors to have access to hormonal blockers for puberty and other cross-sex hormones to help them avoid suicide, it is reasonable to expect the rate of young deaths to fall in the states with the provision that allows minors to access these drugs without parental consent following 2010. There shouldn't be any differences in the rates of suicide rate among teenagers depending on whether states have an option that allows minors access to health care without parental permission prior to the year 2010.
His model, however, found “strong evidence for the claim that suicides among young people have increased significantly since 2010 in states that have a policy allowing minors to access routine health care without parental consent.”
“That rise in suicide rates increased in the year. Prior to the year 2010, whether the state had a similar law or policy had no influence on the rise in suicide rates for those aged 12 to 23,” according to this report. The report adds:
The time of the rise in suicide rates are only found in youngsters, and only after blockers for puberty and hormones for cross-sex are approved and are widely used. Furthermore, this rising trend is found exclusively in the states in which minors are able to have access to these medical treatments without parental consent which raises significant concerns about their impact on suicide risk.
Greene said that his study did not examine directly whether children who are treated with hormonal blockers for puberty and cross-sex hormones are at higher risk of committing suicide. Instead, the study was focused on policies of the state which “facilitate minors accessing those interventions without parental consent and finds that those policies raise suicide risks among young people.”
“To believe that easier access to puberty blockers and cross-sex hormones are not the cause of elevated suicide risk in those states, one would have to be able to imagine other medical interventions that only became widely available after 2010 and would only affect young people,” Greene asserts.
“The lack of theoretically plausible alternatives strengthens the case for concluding that cross-sex medical interventions are the cause of the observed increase in suicide among young people,” he continued.
The World Professional Association for Transgender Health (WPATH) along with the Endocrine Society state that, in addition to being completely safe and completely reversible, puberty blockers can allow an opportunity for adolescents to consider the gender which they decide to live with. They also assert that having access to “gender-affirming” care reduces suicide rates.
These groups, such as those of the American Academy of Pediatrics (AAP) are being used as experts by major institutions, Democrats, and the Biden administration, are seeking to distribute the medication to children who are struggling.
Greene's study disproves these assertions, based on the reality that the results of these medications as treatments for minors with gender dysphoria have “never been subjected to a large-scale randomized controlled trial (RCT).”